Corneilus Stephens

Corneilus Stephens serves as a key procurement lead within the Office of the Assistant Secretary for Preparedness and Response at the Department of Health and Human Services, where he supports the acquisition of critical medical countermeasures to address public health emergencies. His responsibilities encompass managing complex contracting actions for biodefense-related research, development, and manufacturing capabilities, ensuring rapid deployment of vaccines, therapeutics, and diagnostic tools. Stephens operates within a high-stakes, time-sensitive environment, prioritizing agile acquisition pathways to meet national preparedness objectives under the BARDA mission. His portfolio centers on advanced biomedical technologies and supporting services essential to national security and pandemic response. Stephens maintains consistent contracting relationships with specialized biotechnology and pharmaceutical firms, including Cidara Therapeutics, Aquestive Therapeutics, Rafah Laboratories, and Osivax. These partnerships reflect a focus on innovative drug delivery systems, antiviral therapeutics, and vaccine platform technologies. His procurement approach emphasizes collaboration with niche, high-technical-capability vendors capable of rapid scale-up and regulatory compliance, often engaging through Other Transaction Authorities and non-traditional contracting mechanisms to expedite innovation. Stephens’ contracting activity shows no reliance on socioeconomic set-asides, with 100% of awards issued under full and open competition. This reflects a strategic prioritization of technical capability and mission urgency over socioeconomic preferences, aligning with BARDA’s mandate to secure the most effective countermeasures without delay. While small business participation is not formally structured through set-asides, vendors of all sizes are evaluated on technical merit and readiness to deliver under exigent conditions. His primary procurement focus lies in NAICS 541714 (Biotechnology R&D), where he sources cutting-edge research in immunology and antiviral development, complemented by NAICS 541512 for computational modeling and systems design services critical to vaccine optimization. A secondary, atypical focus on NAICS 721110 suggests potential support for temporary operational facilities or emergency response logistics infrastructure, indicating a broad, mission-driven approach to securing all necessary enablers for public health readiness.